myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study
D'Anna R, Scilipoti A, Giordano D, Caruso C, Cannata ML, Interdonato ML, Corrado F, Di Benedetto A
Published in Diabetes Care
Methodology
Prospective randomised placebo-controlled trial of myo-inositol 4 g/day from the first trimester in pregnant women with a family history of type 2 diabetes, with gestational diabetes incidence as the primary outcome.
Key Findings
Gestational diabetes incidence was significantly lower with myo-inositol than placebo, alongside lower fetal macrosomia rates and improved insulin resistance measures.
Conclusions
Myo-inositol reduces gestational diabetes risk in at-risk pregnancies.
Limitations
Single-centre Italian population; open outcome adjudication risks; not generalisable to all pregnancies.
Supplements Studied
Gestational diabetes incidence was significantly lower with myo-inositol than placebo in women with a family history of type 2 diabetes.
Outcomes Measured
Gestational diabetes incidence was significantly lower with myo-inositol than placebo, alongside lower fetal macrosomia rates and improved insulin resistance measures.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Academic (University of Messina)
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.